Rheumatic arthritis (RA) is a complex autoimmune disease characterized by chronic inflammation and joint destruction.Recent progress in the study of RA has been centered around pinpointing biomarkers that can assist in early detection, monitoring the disease, and tailoring treatment plans to the individual.While conventional biomarkers like rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) have played a significant role in RA diagnosis, their precision and accuracy exhibit variability.Novel biomarkers, such as microRNAs (miRNAs/miR) and specific cytokines like interleukin-6 (IL-6), can provide deeper insights into disease mechanisms and monitor therapeutic responses.Despite advancements in biomarkers research, challenges remain in effectively standardizing and integrating biomarker assays into clinical practice.Future directions in biomarker research promise to enhance precision medicine approaches and improve outcomes for RA patients.This study aims to discuss the current landscape of biomarkers in RA, focusing on critical indicators such as RF, ACPA, C-reactive protein (CRP), and other novel markers.
No takes yet. Share an insight, caveat, or question.
Kruszewski et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: